Convatec, a global leader in medical products and technologies, has announced plans to invest £500million in the UK including a new state-of-the-art R&D hub in Manchester.
The hub is planned to open 2027, which is due to be located at Citylabs 4.0, the newest phase of Bruntwood SciTech’s world-leading health innovation campus.
The £42 million, 125,000 sq ft facility will provide a state-of-the-art base for Convatec’s teams, as well as offering direct connections to highly skilled talent, funding, universities, the NHS and mentorship.
It will also house cutting-edge analytical R&D capabilities, regulatory functions, and digital health innovation, positioning Convatec at the forefront of medical technology development.
The new Manchester R&D hub will be home for around 200 highly skilled colleagues, largely transferring from Convatec’s existing Deeside R&D site, with plans for further growth in the years ahead.
Convatec’s manufacturing site in Deeside, North Wales, will remain a cornerstone of its global operations and is unaffected by this change, with around 400 employees continuing to be based there after the move completes in 2027.
Jonny Mason, Interim Chief Executive Officer at Convatec, said:
“Today’s announcement marks an exciting moment in Convatec’s commitment to pioneering trusted medical solutions to improve the lives we touch. Our plans to invest more than $1 billion – anchored by major expansion plans in both the United States and the United Kingdom – demonstrates our unwavering commitment to advancing healthcare innovation for people living with chronic conditions around the world.”
Dr. Divakar Ramakrishnan, Chief Technology Officer and Head of Research & Development at Convatec, said:
“The significant expansion of our R&D capabilities in Boston and plans to establish a new flagship centre in Manchester are investments in the talent, technology, and infrastructure needed to accelerate innovation in pioneering trusted chronic care solutions. They reinforce our belief in the strength of the US and UK life sciences sectors and position Convatec at the forefront of medical technology innovation for years to come.”
